

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/769,245	01/26/2001	Jeffrey Ray Stout	BO 44277	5103
100	590 12/04/2001		EVAM	DICD
YOUNG & THOMPSON 745 SOUTH 23RD STREET 2ND FLOOR ARLINGTON, VA 22202			EXAMINER	
			CHOI, FRANK I	
		•	ART UNIT	PAPER NUMBER
			1616	4
			DATE MAILED: 12/04/2001	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
		09/769,245	STOUT ET AL.
	Office Acti n Summary	Examiner	Art Unit
	.•	Frank I Choi	1616
	The MAILING DATE of this communication app	pears on the c ver sheet with	the correspondenc address
eri d for	Reply		
THE N - Extens after S - If the p - If NO	PRTENED STATUTORY PERIOD FOR REPLANDING DATE OF THIS COMMUNICATION. Sions of time may be available under the provisions of 37 CFR 1.15 (6) MONTHS from the mailing date of this communication. Deriod for reply specified above is less than thirty (30) days, a represent of the provision of the period for reply is specified above, the maximum statutory period to reply within the set or extended period for reply will, by statute the period by the Office later than three months after the mailing patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a repl by within the statutory minimum of thirty (3 will apply and will expire SIX (6) MONTH	y be timely filed 30) days will be considered timely. IS from the mailing date of this communication. NDONED (35 U.S.C. § 133).
1)	Responsive to communication(s) filed on	•	
2a)□		nis action is non-final.	
3)	Since this application is in condition for allow closed in accordance with the practice under	rance except for formal matter Ex parte Quayle, 1935 C.D.	ers, prosecution as to the merits is
Dispositi	on of Claims		
4)🛛	Claim(s) 1-22 is/are pending in the application	n.	
•	4a) Of the above claim(s) is/are withdra	awn from consideration.	
5)	Claim(s) is/are allowed.		•
6)⊠	Claim(s) 1-22 is/are rejected.		
7)	Claim(s) is/are objected to.		
8)	Claim(s) are subject to restriction and/	or election requirement.	
Applicati	ion Papers		
9)	The specification is objected to by the Examin	er.	
10)	The drawing(s) filed on is/are: a)☐ acc	epted or b) objected to by th	e Examiner.
	Applicant may not request that any objection to	the drawing(s) be held in abeya	nce. See 37 CFR 1.85(a).
11)	The proposed drawing correction filed on	is: a)[_] approved b)[_] di	sapproved by the Examiner.
	If approved, corrected drawings are required in		
12)	The oath or declaration is objected to by the E	Examiner.	
Pri rity	under 35 U.S.C. §§ 119 and 120		140(-) (-1) (5)
13)	Acknowledgment is made of a claim for forei	gn priority under 35 U.S.C. §	§ 119(a)-(d) or (τ).
a)	☐ All b)☐ Some * c)☐ None of:		
	1. Certified copies of the priority docume	nts have been received.	
	2. Certified copies of the priority docume	nts have been received in A	pplication No
	3. Copies of the certified copies of the prapplication from the International See the attached detailed Office action for a li		
14)	Acknowledgment is made of a claim for dome	stic priority under 35 U.S.C.	§ 119(e) (to a provisional application).
	a) The translation of the foreign language Acknowledgment is made of a claim for dome	provisional application has be	een received.
Attachme			
1) Not	ice of References Cited (PTO-892) ice of Draftsperson's Patent Drawing Review (PTO-948) ormation Disclosure Statement(s) (PTO-1449) Paper No(s	5) Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)

Art Unit: 1616

DETAILED ACTION

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 8, 9,12, 14, 16, 17 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 8, 9 recite "creatine salt" which renders the claims indefinite as same term is used in claim 5 which appears to be different in scope. To avoid confusion, Examiner suggests using "organic creatine salt".

Claim 9 recites "wherein the creatine salt comprises an anionic component" which renders the claim indefinite as the above impliedly excludes creatine since it is not recited after the transitional phrase "comprises". Examiner suggests using "further comprises".

Claim 12 recites the limitation "anionic component of the creatine salt". There is insufficient antecedent basis for this limitation in the claim. Neither Claim 11 nor Claim 1 recite the above.

A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. In the present instance, claim 14 recites the broad recitations "creatine", "phosphorus" and "buffer", and the claim also recites "creatine citrate", "phosphate" and "a combination of carbonate and/or bicarbonate and citrate" which are the narrower statement of the range/limitations, respectively.

Art Unit: 1616

Claim 16 recites "pentose" and "ribose". Claim 17 recites "sodium salt" and "sodium phosphate".

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gardiner (U.S. Pat. 6,136,339) in view of Weinstein et al. (U.S. Pat. 6,013,290), WO 96/04240, Fang (U.S. Pat. 5, 886,040), Webster's Dictionary (10th Ed.), Odian et al. (Schaum's Outline), Hultman et al. (U.S. Pat. 5,767,159) and St. Cyr et al. (U.S. Pat. 6,159,942).

Gardiner teaches a food supplement comprising creatine, including creatine monohydrate, creatine citrate and creatine pyruvate and phosphorous and salts thereof (Column 2, lines 20-24, Column 3, lines 34-39, Column 5, lines 5-55). A method of administration is taught where administration of the supplement continued until the desired muscle size or strength is obtained and then reduced amounts of the supplement is administered to maintain said muscle size or strength (Column 4, lines 47-60).

Weinstein et al. teaches that for person's who are exercising and replenishing lost water, sodium is necessary to prevent hyponatremia and allow optimal restoration of lost fluid (Column 4, lines 20-28). Is taught that carbohydrates are useful for recovery of muscle glycogen after exercising (Column 4, lines 30-68). It is taught that sodium bicarbonate, sodium citrate and potassium citrate are alkaline buffers improve performance in athletes utilizing the anaerobic

Art Unit: 1616

energy system by counteracting the increasing acidity of blood caused by exercise and which acidity contributes to fatigue (Column 5, lines 50-58). It is taught that creatine supplementation for allows high rates of ATP resynthesis (Column 6, lines 7-14). It is taught that phosphates and pyruvates have or may have positive effects on exercise (Column 6, lines 20-24).

WO 96/04240 teaches that mono-, bi- or tri-carboxylic acid salts of creatine, including citrate, maleate, fumarate, tartrate or malate, exhibit increased hydrosolubility and increased bioavailability over creatine, with the citrate, maleate and tartrate salts exhibiting a water solubility of 10 g/100 ml, 19 g/100 ml and 8.5 g/100 ml, respectively (Pgs. 1-3).

Fang teaches that creatine pyruvate is more water soluble than creatine and enables the optimal biofunctionality of both creatine and pyruvate in enhancing energy and metabolic rates (Column 8, lines 19-35).

Webster's Dictionary (10th Ed.) defines "precursor" as a substance from which another substance is formed (Pg. 917).

Odian et al. teaches that in the Kreb's cycle, that pyruvate is used to form citrate fumarate and malate, that citrate is used to form fumarate and malate, and that malate is used to form pyruvate (Pgs. 450, 452).

Hultman et al. teaches that creatine phosphate is the substrate in muscular tissue which gives the fastest resynthesis of ATP and that formulations containing creatine include effervescent powders which may be dissolved in water (Column 1, lines 20-35, Column 2, lines 23-27).

St. Cyr et al. teaches that energy buildup in muscle cells is through oxidative phosphorylation which replenishes ATP by breakdown of circulating fatty acids, glucose and

Art Unit: 1616

intramuscular glycogen and triglcerides and anerobic phosphorylation which provides ATP from creatine phosphate, glucose and intramuscular glycogen via kinase reactions (Column 1, lines 29-43). It is taught that irrespective of the substrates used for the generation of ATP, ATP cannot be synthesized unless that precursors of the ATP molecule itself are available (Column 1, lines 60-64). It is taught that pentoses, such as ribose, allow athletes to exercise longer with greater energy and that combination with creatine, pyruvate, electrolytes and/or carbohydrates enhance the pentose benefit (Column 3, lines 10-57).

The difference between the prior art and the claimed invention is that the prior art does not expressly disclose a composition or method of using the same, comprising creatine, a phosphorous supplement which provides at least 75% of the recommended daily dose value per serving and a blood buffer. However, the prior art amply suggests the same as it is known in the art to prepare nutritional supplements containing creatine, phosphorus and blood buffers for increasing energy and increasing anaerobic work capacity. As such, it would have been well within the skill of and one of ordinary skill in the art would have been motivated to modify the prior art as above with the expectation that the combination of creatine, phosphorus, sodium, blood buffers, organic salts of creatine, Krebs cycle intermediates and precursors thereof, carbohydrates, pentoses would be effective increasing tissue cell energy and anaerobic work capacity and that after the initial adminstration that the increased anerobic work capacity could be maintained with lesser doses of the composition.

Therefore, the claimed invention, as a whole, would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made, because every element of the invention has been collectively taught by the combined teachings of the references.

Art Unit: 1616

Conclusion

A facsimile center has been established in Technology Center 1600. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier numbers for accessing the facsimile machines are (703) 308-4556 or (703) 305-3592.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Choi whose telephone number is (703) 308-0067. Examiner maintains a flexible schedule. However, Examiner may generally be reached Monday-Friday, 8:00 am – 5:30 pm (EST), except the first Friday of the each biweek which is Examiner's normally scheduled day off.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's Supervisor, Mr. José Dees, can be reached on (703) 308-4628. Additionally, Technology Center 1600's Receptionist and Customer Service can be reached at (703) 308-1235 and (703) 308-0198, respectively.

FIC

November 29, 2001

JOHN PAK PRIMARY EXAMINER GROUP 1200

Ash da